title: The role of patient training in the management of seasonal rhinitis and asthma: clinical implications.
abstract: BACKGROUND
  Allergic rhinitis is an inflammatory disease often associated with bronchial asthma. Intranasal corticosteroids and oral antihistamines are the first-choice drugs. Patient training is relevant to asthma management, but little is known about its impact on rhinitis. We evaluated the role of patient training in the treatment of allergic rhinitis and its effects on nasal and bronchial symptoms.
  
  
  METHODS
  One hundred and one patients (M/F = 62/39, age range 12-62 years) with pollen-induced rhinitis (32 with concomitant mild asthma) were enrolled. They were randomized into three groups: A (n = 30) with drug therapy alone, B (n = 35) with drug therapy plus training on the use of nasal spray, and C (n = 36) the same as B plus a lesson on rhinitis and asthma. All patients received mometasone furoate nasal spray for 8 weeks as regular therapy, plus rescue medications on demand. Symptoms and drug consumption were evaluated during the pollen season.
  
  
  RESULTS
  The rate of noncompliance/dropout was highest in the untrained patients (P = 0.001). No difference in nasal symptoms was seen among the three groups. On the other hand, group C had significantly fewer asthma symptoms (P = 0.02) and less albuterol use (P = 0.005) than group A. Moreover, the trained group globally used less rescue medication than the other groups (P = 0.02).
  
  
  CONCLUSIONS
  Detailed training of patients seems to improve compliance with treatment, reduce concomitant asthma symptoms, and reduce the use of symptomatic drugs.
authors.affiliation: Respiratory Diseases, Allergy Service, University of Turin, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Gani
authors.forename: E
authors.initials: E
authors.lastname: Pozzi
authors.forename: M A
authors.initials: MA
authors.lastname: Crivellaro
authors.forename: G
authors.initials: G
authors.lastname: Senna
authors.forename: M
authors.initials: M
authors.lastname: Landi
authors.forename: C
authors.initials: C
authors.lastname: Lombardi
authors.forename: G W
authors.initials: GW
authors.lastname: Canonica
authors.forename: G
authors.initials: G
authors.lastname: Passalacqua
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D002648:Child; D019468:Disease Management; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D010349:Patient Compliance; D010352:Patient Dropouts; D010353:Patient Education as Topic; D011244:Pregnadienediols / Q000008:administration & dosage / Q000627:therapeutic use; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*
chemical_list: D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate